Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990908 | 1.00 | GRM5 (0.63) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL3242724 | 0.98 | RAB9A (0.65) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL31392086 | 0.98 | RAB9A (0.65) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL423224 | 0.95 | RAB9A (0.65) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL28477730 | 0.85 | RAB9A (0.62) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL15444999 | 0.85 | KMT2A (0.68) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL524766 | 0.85 | HRH3 (0.59) | GRM5RAB9AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL712714 | 0.84 | RAB9A (0.68) | GRM5RAB9AHPGDKDM4EPOLB | |
| SCHEMBL20460493 | 0.84 | HPGD (0.64) | GRM5RAB9AL3MBTL1HPGDALDH1A1 | |
| SCHEMBL28392755 | 0.84 | RAB9A (0.60) | GRM5RAB9AL3MBTL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| EP-3357916-A1 | BENZAMIDE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | GRM5 3093/4885RAB9A 1551/4885L3MBTL1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.